Is there an interplay between the SARS-CoV-2 spike protein and Platelet-Activating factor?
ADP
collagen
coronavirus
human platelet-rich plasma
monocytes
platelet-activating factor
platelets
spike protein
thrombin
vaccines
Journal
BioFactors (Oxford, England)
ISSN: 1872-8081
Titre abrégé: Biofactors
Pays: Netherlands
ID NLM: 8807441
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
19
04
2022
accepted:
27
06
2022
pubmed:
20
7
2022
medline:
24
12
2022
entrez:
19
7
2022
Statut:
ppublish
Résumé
Previous publications have reported a potent effect of COVID-19 on platelet function and that the Spike protein enhances washed human platelet aggregation induced by various agonists. This study aims to evaluate whether mRNA vaccination for COVID-19 affects human platelet-rich plasma (hPRP) aggregation response, whether a recombinant Spike protein modulates PAF-induced aggregation in hPRP and in washed rabbit platelets (WRP), and to investigate the effect of recombinant Spike protein on the PAF production in the U-937 cell line. Our results showed that PRP from vaccinated individuals exhibited ex vivo lower EC
Identifiants
pubmed: 35852257
doi: 10.1002/biof.1877
pmc: PMC9349578
doi:
Substances chimiques
spike protein, SARS-CoV-2
0
Spike Glycoprotein, Coronavirus
0
Platelet Activating Factor
0
Collagen
9007-34-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1271-1283Informations de copyright
© 2022 International Union of Biochemistry and Molecular Biology.
Références
Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N. Engl. J. Med. 2020;383:288-90.
Ranucci M, Ballotta A, Di Dedda U, Baryshnikova E, Dei Poli M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J. Thromb. Haemost. 2020;18:1747-51.
Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N. Engl. J. Med. 2020;382:e38.
Litvinov RI, Evtugina NG, Peshkova AD, Safiullina SI, Andrianova IA, Khabirova AI, et al. Altered platelet and coagulation function in moderate-to-severe COVID-19. Sci. Rep. 2021;11:16290.
Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T, Weigand M, et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation. 2020;142:1176-89.
Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology. 2021;88:15-27.
Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al. Platelet gene expression and function in patients with COVID-19. Blood. 2020;136:1317-29.
Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J. Hematol. Oncol. 2020;13:120.
Li T, Yang Y, Li Y, Wang Z, Ma F, Luo R, et al. Platelets mediate inflammatory monocyte activation by SARS-CoV-2 spike protein. J. Clin. Invest. 2022;132:e150101.
Zhao Y, Kuang M, Li J, Zhu L, Jia Z, Guo X, et al. SARS-CoV-2 spike protein interacts with and activates TLR4. Cell Res. 2021;31:818-20.
Maugeri N, De Lorenzo R, Clementi N, Antonia Diotti R, Criscuolo E, et al. Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19. J. Thromb. Haemost. 2022;20:434-48.
Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J. Biol. Chem. 1979;254:9355-8.
Antonopoulou S, Nomikos T, Karantonis HC, Fragopoulou E, Demopoulos CA. PAF, a potent lipid mediator. In: Tselepis A, editor. Bioactive phospholipids: role in inflammation and atherosclerosis. Kerala, India: Transworld Research Network; 2008. p. 85-134.
McManus LM, Hanahan DJ, Pinckard RN. Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. J. Clin. Invest. 1981;67:903-6.
Chesney CM, Pifer DD, Byers LW, Muirhead EE. Effect of platelet-activating factor (PAF) on human platelets. Blood. 1982;59:582-5.
Shah N, Kumar K, Shah N. PAF physiology in target organ systems-a deep dive to understand the PAF mystery in pathogenesis of disease. Heart. 2021;2:551-60.
Theoharides TC, Antonopoulou S, Demopoulos CA. Coronavirus 2019, microthromboses, and platelet activating factor. Clin. Ther. 2020;42:1850-2.
Demopoulos C, Antonopoulou S, Theoharides TC. COVID-19, microthromboses, inflammation, and platelet activating factor. Biofactors. 2020;46:927-33.
Klein M, Dao V, Khan F. A review of platelet-activating factor as a potential contributor to morbidity and mortality associated with severe COVID-19. Clin. Appl. Thromb. Hemost. 2021;27:10760296211051764.
Zabetakis I, Lordan R, Norton C, Tsoupras A. COVID-19: the inflammation link and the role of nutrition in potential mitigation. Nutrients. 2020;12:1466.
Detopoulou P, Demopoulos CA, Antonopoulou S. Micronutrients, phytochemicals and Mediterranean diet: a potential protective role against COVID-19 through modulation of PAF actions and metabolism. Nutrients. 2021;13:462.
Harayama T, Shindou H, Ogasawara R, Suwabe A, Shimizu T. Identification of a novel noninflammatory biosynthetic pathway of platelet-activating factor. J. Biol. Chem. 2008;283:11097-106.
Barberis E, Timo S, Amede E, Vanella VV, Puricelli C, et al. Large-scale plasma analysis revealed new mechanisms and molecules associated with the host response to SARS-CoV-2. Int. J. Mol. Sci. 2020;21:8623.
Snyder F. CDP-choline:alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor. Biochim. Biophys. Acta. 1997;1348:111-6.
Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc. Drugs Ther. 2009;23:73-83.
Li Y, Jiang Y, Zhang Y, Li N, Yin Q, Liu L, et al. Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients. Sci. Rep. 2021;11:6811.
Antonopoulou S, Nomikos T, Fragopoulou E, Karantonis HC. Isolation and characterization of cyanobacterial lipids with bioactivity towards platelet-aggregation. In: Kleiner D, Mohanty P, editors. Protocols on algal and cyanobacterial research. New Delhi, India: Narosa Publishing House; 2010. p. 71-101.
Vlachogianni IC, Fragopoulou E, Stamatakis GM, Kostakis IK, Antonopoulou S. Platelet activating factor (PAF) biosynthesis is inhibited by phenolic compounds in U-937 cells under inflammatory conditions. Prostaglandins Other Lipid Mediat. 2015;121:176-83.
Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959;37:911-7.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72:248-54.
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983;65:55-63.
Demopoulos CA, Andrikopoulos NK, Antonopoulou S. A simple and precise method for the routine determination of platelet-activating factor in blood and urine. Lipids. 1994;29:305-9.
Gavriil L, Detopoulou M, Petsini F, Antonopoulou S, Fragopoulou E. Consumption of plant extract supplement reduces platelet activating factor-induced platelet aggregation and increases platelet activating factor catabolism: a randomised, double-blind and placebo-controlled trial. Br. J. Nutr. 2019;121:982-91.
Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pão CRR, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020;136:1330-41.
Nguer CM, Treton D, Rola-Pleszczynski M, Mishal Z, Thomas Y, Galanaud P, et al. Regulation of platelet-activating factor receptor expression in human B cells and B cell lines. Lipids. 1996;31:1051-8.
Calabresse C, Nguer MC, Pellegrini O, Benveniste J, Richard Y, Thomas YN. Induction of high-affinity paf receptor expression during T cell activation. Eur. J. Immunol. 1992;22:1349-55.
Angeli F, Spanevello A, Reboldi G, Visca D, Verdecchia P. SARS-CoV-2 vaccines: lights and shadows. Eur. J. Intern. Med. 2021;88:1-8.
Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am. J. Clin. Pathol. 2005;123:172-83.
Orchard MA, Waddell KA, Lewis PJ, Blair IA. Thromboxane synthase inhibition causes re-direction of prostaglandin endoperoxides to prostaglandin D2 during collagen stimulated aggregation of human platelet rich plasma. Thromb. Res. 1985;39:701-10.
Sato A, Yokoyama I, Ebina K. Angiotensin peptides attenuate platelet-activating factor-induced inflammatory activity in rats. Peptides. 2015;73:60-6.
Kawaguchi H, Sawa H, Yasuda H. Mechanism of increased angiotensin-converting enzyme activity stimulated by platelet-activating factor. Biochim. Biophys. Acta. 1990;1052:503-8.
Proudfoot JM, Croft KD, Puddey IB, Beilin LJ. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. J. Pharmacol. Exp. Ther. 2003;305:846-53.
Erfinanda L, Ravindran K, Kohse F, Gallo K, Preissner R, Walther T, et al. Oestrogen-mediated upregulation of the mas receptor contributes to sex differences in acute lung injury and lung vascular barrier regulation. Eur. Respir. J. 2021;57:2000921.
Tsai H-J, Shih C-C, Chang K-Y, Liao M-H, Liaw W-J, Wu CC, et al. Angiotensin-(1-7) treatment blocks lipopolysaccharide-induced organ damage, platelet dysfunction, and IL-6 and nitric oxide production in rats. Sci. Rep. 2021;11:610.
Verouti SN, Fragopoulou E, Karantonis HC, Dimitriou AA, Tselepis AD, Antonopoulou S, et al. PAF effects on MCP-1 and IL-6 secretion in U-937 monocytes in comparison with oxLDL and IL-1β effects. Atherosclerosis. 2011;219:519-25.
Karwaciak I, Sałkowska A, Karaś K, Dastych J, Ratajewski M. Nucleocapsid and spike proteins of the coronavirus SARS-CoV-2 induce IL6 in monocytes and macrophages-potential implications for cytokine storm syndrome. Vaccines (Basel). 2021;9:54.
Gowda P, Patrick S, Joshi SD, Kumawat RK, Sen E. Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication. Cytokine. 2021;142:155496.
Theoharides TC. Could SARS-CoV-2 spike protein be responsible for long-COVID syndrome? Mol. Neurobiol. 2022;59:1850-61.
Faggio C, Sureda A, Morabito S, Sanches-Silva A, Mocan A, Nabavi SF, et al. Flavonoids and platelet aggregation: a brief review. Eur. J. Pharmacol. 2017;807:91-101.
Antonopoulou S, Detopoulou M, Fragopoulou E, Nomikos T, Mikellidi Α, Yannakoulia M, et al. Consumption of yogurt enriched with polar lipids from olive oil by-products reduces platelet sensitivity against platelet activating factor and inflammatory indices: a randomized, double-blind clinical trial. Human Nutr Metab. 2022;28:200145.
Babic I, Bojic M, Males Z, Zadro R, Gojceta K, et al. Influence of flavonoids' lipophilicity on platelet aggregation. Acta Pharm. 2019;69:607-19.
Balestrieri ML, Castaldo D, Balestrieri C, Quagliuolo L, Giovane A, Servillo L. Modulation by flavonoids of PAF and related phospholipids in endothelial cells during oxidative stress. J. Lipid Res. 2003;44:380-7.
Alevizos M, Karagkouni A, Vasiadi M, Sismanopoulos N, Makris M, Kalogeromitros D, et al. Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor. Ann. Allergy Asthma Immunol. 2013;111:542-7.
Theoharides TC, Guerra L, Patel K. Successful treatment of a patient with severe COVID-19 using an integrated approach addressing mast cells and their mediators. Int. J. Infect. Dis. 2022;118:164-6.